This review summarizes recent clinical trials on antiplatelet therapy for secondary stroke prevention, addressing optimal ASA dosing, combination therapies, and new agents.
Should not yet change antiplatelet practice for secondary stroke prevention; leaves open optimal ASA dosing and combination strategies.
SUMMARY Stroke is a leading cause of long‐term disability and death in developed countries. The primary medical strategy for secondary prevention of stroke is antiplatelet therapy. Although the clinical value of acetylsalicylic acid (ASA) is well recognised for preventing secondary stroke, several questions remain. What is the optimal dose of ASA to prevent stroke? Would combining ASA with another antiplatelet drug increase efficacy? Do new agents currently under development offer additional benefits? Many of the recent clinical trials address these questions. This review article summarises the results of these trials in the context of evolving strategies for stroke prevention, including the management of recurrent transient ischaemic attacks (TIAs), side‐effects of ASA, and economic issues.
No takes yet. Share an insight, caveat, or question.
HC Diener (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: